🧬 Messenger RNA (mRNA) technology, which enabled the rapid development of COVID-19 vaccines, is now being utilized to create personalized cancer vaccines. Companies like BioNTech and Moderna, in collaboration with the UK’s National Health Service, are leading this initiative, supported by significant investments and advancements in genetic sequencing and artificial intelligence.
🔬 These vaccines analyze individual tumors genetically, identify their mutations, and manufacture personalized doses that train the immune system to detect and combat specific cancer recurrences. Clinical trials have commenced in several countries, including Spain, and are in phase three, aiming for approval in 2025.
💡 These vaccines are expected to complement traditional treatments, such as chemotherapy, and help prevent recurrences after surgery. Public confidence in mRNA technology following the pandemic is accelerating its application in oncology, marking a milestone in personalized medicine.
